Zurich Cantonal Bank
NVAX icon

Zurich Cantonal Bank’s Novavax NVAX Stock Holding History

Zurich Cantonal Bank’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-113,623
Closed -$764K – 3185
2025
Q4 		$764K Buy
+113,623
New +$857K ﹤0.01% 1514

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Zurich Cantonal Bank's NVAX Position: Q2 2026 in Review

Zurich Cantonal Bank held its Novavax (NVAX) position steady in Q2 2026 at 47,980 shares worth $452K. The position accounts for ﹤0.01% of the portfolio, ranked #1999.

Zurich Cantonal Bank first reported a position in NVAX in Q1 2015 and has held it in 43 quarters since. The position peaked at $4.46M in Q3 2021. 267 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Zurich Cantonal Bank held 47,980 shares of Novavax worth $452K as of Q2 2026.
  • Zurich Cantonal Bank left its Novavax share count unchanged in Q2 2026.
  • Novavax made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1999 holding.
  • Zurich Cantonal Bank first reported a position in Novavax in Q1 2015 and has held it in 43 quarters since.
  • Zurich Cantonal Bank's Novavax position peaked at $4.46M in Q3 2021.
  • 267 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.